ArticleTranslational andrology and urology2026
Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transurethral resection of bladder tumor (TURBT) remains the standard surgical approach for non-muscle invasive bladder cancer (NMIBC). However, whether newer laser-based/en bloc techniques translate into durable oncologic benefits beyond perioperative and specimen-quality advantages remains controversial, and population-level evidence on recurrence and progression-particularly among patients who subsequently recur-is limited. This study compared oncologic outcomes between TURBT and transurethral laser excision of bladder tumor (TULBT) in patients with NMIBC using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: In this SEER retrospective cohort, we identified first primary NMIBC [stage 0a/0is/I according to the American Joint Committee on Cancer (AJCC) 8th edition] with urothelial histologies (ICD-O-3: 8120/3, 8130/3, 8131/3) treated with TURBT or TULBT (SEER surgery codes 14, 24-25, 27). Variables included recurrence-free survival (RFS), demographics, tumor AJCC stage, tumor progression, and overall survival (OS). RFS was defined as the time from index diagnosis to a subsequent primary bladder cancer (BCA) under SEER multiple-primary rules; progression was defined as muscle-invasive bladder cancer (MIBC) (AJCC II-IV) at recurrence. As the primary analysis, multivariable logistic regression and Cox proportional hazards models were performed in the full cohort to evaluate tumor progression and OS, with 1:3 propensity score matching (PSM) used for sensitivity analyses. Results: A total of 682 patients were included (TULBT, n=56; TURBT, n=626). In the raw cohort, MIBC at recurrence was more frequent after TULBT (46.4% Conclusions: TULBT is associated with longer RFS than TURBT in NMIBC, albeit with no clear benefit in tumor progression. Its survival advantage likely stems from delaying recurrence. These findings are exploratory and hypothesis-generating and warrant validation in prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.